Skip to main content

Table 2 Univariate analysis of prognostic factors

From: Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the malignant progression of pancreatic cancer by triggering malignancy-related positive feedback loops signaling

Variable Cases Events Mean survival (months) HRa(95% CIb) p
Gender      0.504
 Male 61 47 16.176 1  
 Female 47 37 19.699 0.862 (0.559-1.331)  
Age (y)      0.176
 < 60 47 35 21.381 1  
 ≥ 60 61 49 15.254 1.352 (0.874-2.092)  
Location of tumor      0.026*
 Head 72 52 20.770 1  
 Body and tail 36 32 12.235 1.655 (1.062-2.579)  
Size of tumor (cm)      0.358
 ≤ 2 22 67 20.116 1  
 >2 86 17 17.290 1.285 (0.753-2.192)  
Differentiation      <0.001*
 Well 15 8 34.953 1  
 Moderate 83 66 15.803 2.532 (1.202-5.332) 0.015*
 Poor 10 10 5.700 7.624 (2.918-19.916) <0.001*
Nerve infiltration      0.699
 No 38 29 21.137 1  
 Yes 70 55 16.406 1.094 (0.694-1.725)  
TNM staging      0.007*
 IA + IB 15 12 24.448 1  
 IIA 33 25 17.483 1.371 (0.684-2.751) 0.374
 IIB 46 34 18.785 1.507 (0.777-2.925) 0.225
 III + IV 14 13 6.982 3.729 (1.664-8.358)) 0.001*
Serum CA19-9 (kU/L)      0.014*
 ≤ 39 31 16 28.993 1  
 > 39 77 68 14.556 1.988 (1.150-3.436)  
Serum CA50 (kU/L)      0.065*
 ≤ 25 49 30 24.091 1  
 > 25 59 54 14.459 1.529 (0.975-2.398)  
Serum CEA (μg/L)      0.032*
 ≤ 5 64 44 22.116 1  
 > 5 44 40 12.072 1.609 (1.041-2.488)  
MUC4 (2-ΔCt)      <0.001*
 Low (<0.056) 75 54 22.101 1  
 High (≥0.056) 33 30 8.054 2.595 (1.612-4.179)  
MUC4/Y (2-ΔCt)      0.003*
 Low (<0.0044) 79 58 21.126 1  
 High (≥0.0044) 29 26 8.835 2.077 (1.283-3.365)  
  1. aHR, hazard ratio; bCI, confidence interval; * P ≤ 0.10.